An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023

BACKGROUND: We present the study rationale and design of the JGOG3023 study, an open-label, parallel-arm, randomized, phase II trial that aimed to assess the efficacy and safety of chemotherapy with or without bevacizumab in patients with platinum-resistant recurrent epithelial ovarian, fallopian tu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Shoji, Tadahiro, Komiyama, Shinichi, Kigawa, Junzo, Tanabe, Hiroshi, Kato, Kazuyoshi, Itamochi, Hiroaki, Fujiwara, Hiroyuki, Kamiura, Shoji, Hamano, Tetsutaro, Sugiyama, Toru
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2018
Témata:
Study Protocol
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6069952/
https://ncbi.nlm.nih.gov/pubmed/30064406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4505-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky